Company
Headquarters: Shanghai, China
Employees: 591
CN¥12.71 Billion
CNY as of July 1, 2024
US$1.75 Billion
| Company | Market Cap (USD) |
|---|---|
| Abbott | $178.02 B |
| Stryker Corporation | $126.48 B |
| Boston Scientific Corporation | $112.32 B |
| Medtronic | $98.95 B |
| Edwards Lifesciences Corporation | $55.63 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Shanghai MicroPort Endovascular MedTech Co., Ltd. develops, manufactures, and sells technologies and products in the healthcare business. The company primarily offers solutions for aortic and peripheral diseases. Its products include TAA and AAA stent graft systems, balloon inflation catheters, and PTA balloon dilatation catheters. The company was founded in 2012 and is based in Shanghai, the People's Republic of China. Shanghai MicroPort Endovascular MedTech Co., Ltd. is a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Shanghai MicroPort Endovascular MedTech Co. Ltd has the following listings and related stock indices.
Stock: SSE: 688016 wb_incandescent